the prevalence of obesity is increasing at an alarming rate but unfortunately only a few medications are currently on the marketobesity is primarily regarded as a disorder of lipid metabolism and the enzymes involved in this process could be selectively targeted to develop antiobesity drugsrecently newer approaches for the treatment of obesity have involved inhibition of dietary triglyceride absorption via inhibition of pancreatic lipase pl as this is the major source of excess caloriesnatural products provide a vast pool of pl inhibitors that can possibly be developed into clinical productsthis article reviews various extracts and secondary metabolites from plants and microbial origin with pl inhibitory activity that can be focused for drug development programs